ArticleEuropean journal of haematology2026
Efficacy and Tolerance of Cladribine for Non-Langerhans Cell Histiocytosis.
Article in European journal of haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundErdheim-Chester Disease (ECD) and Rosai-Dorfman Disease (RDD) Are Rare Non-Langerhans Cell Histiocytoses That Share Several Clinical and Histological Features, Including the Accumulation of CD1a- Histiocytes in Organs. Cladribine, a Purine Analog, Leads to an Overall Response Rate (ORR) of 91% in Langerhans-Cell Histiocytoses. Whether the Same Results Could Be Obtained in Non-Langerhans Cell Histiocytoses Remains To Be Determined. PATIENTS AND
methodsWe retrospectively assessed the efficacy of cladribine according to clinical and radiological responses in consecutive patients with a diagnosis of ECD, RDD, or non-classified non-Langerhans cell histiocytosis.
resultsTwenty-One Patients Were Included in This Study (17 Males, Median Age at Cladribine Treatment 53 Years). The Clinical ORR Was 62% (44% in ECD, 70% in RDD), whereas the Radiological ORR Was 43% (44% in ECD, 30% in RDD). Four of Five Patients With Cranial Nerve Palsy Responded Clinically (80%), whereas Pseudo-Degenerative CNS Involvement Did Not Improve (n = 3). Six Patients With Multisystemic Involvement Did Not Require Additional Treatment After Achieving a Radiological Response (n = 4) or After Achieving Radiological Stable Disease (n = 2), with a Median Follow-Up of 2.3 Years (Range 0.5-9.5). After They Achieved a Radiological Response, 4/9 (44%) Patients Relapsed in a Median Time of 18 Months (Range 6-95). The Safety Profile Showed That 19/19 Patients Experienced Lymphopenia, Whereas Only 2/19 Had Clinical Infectious Events (9%).
conclusionsThese Results Provide New Evidence of the Efficacy of Cladribine in Non-Langerhans Cell Histiocytosis and Brings New Data on the Safety Profile of This Drug in Histiocytoses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.